Novo, Lilly shares rise on Biden's obesity coverage plan | REUTERS
Shares of Novo Nordisk and Eli Lilly surged following President Biden's proposal to expand coverage of anti-obesity drugs for over 7 million people with Medicare and Medicaid health coverage. The proposal has the potential to significantly impact the weight-loss drug market and signals a potential shift in healthcare coverage for obesity treatment. This move could have far-reaching implications for the pharmaceutical industry and healthcare landscape.
!summarize